Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up After Analyst Upgrade

Key Points

• Telix Pharmaceuticals shares rose after RBC upgraded the stock from “hold” to “moderate buy,” opening at $11.93 versus a previous close of $11.31.
• Analyst sentiment is broadly positive, with a consensus “Buy” rating and an average price target of $20.40; Wedbush and HC Wainwright set targets of $22 and $20, respectively.
• The proposed ITM combination could expand Telix’s radiopharmaceutical capabilities, but investors remain concerned about the deal’s size, potential dilution, funding, leverage and integration risks.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s stock price gapped up before the market opened on Tuesday after Royal Bank Of Canada upgraded the stock from a hold rating to a moderate buy rating. The stock had previously closed at $11.31, but opened at $11.93. Telix Pharmaceuticals shares last traded at $11.98, with a volume of 100,454 shares changing hands.

Other research analysts also recently issued research reports about the stock. Wedbush restated an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Monday, September 14th. Citigroup restated a "buy" rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a research note on Friday, August 21st. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $20.40.

Key Stories Impacting Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: RBC upgraded Telix from “hold” to “moderate buy,” signaling improved confidence in the company’s outlook following the recent sell-off. TickerReport coverage of RBC upgrade
• Positive Sentiment: The proposed ITM combination would create a larger radiopharmaceutical company with greater access to radioisotope production, supply capabilities and development assets. Management and industry coverage characterize the deal as a move to build a global sector leader. Telix and ITM merger announcement
• Neutral Sentiment: ASX waivers related to the timing of shares issued as acquisition consideration help facilitate the transaction, but also highlight that the deal involves equity issuance and complex closing requirements. Telix’s merger call provided additional details on the transaction and rationale. Yahoo Finance ASX preview
• Negative Sentiment: Shares fell sharply after investors focused on the acquisition’s size, funding and dilution risks. Reported transaction values range from approximately $1.65 billion on a cash- and debt-free basis to as much as $2.35 billion, while other coverage cites a higher value including broader deal considerations. Investors may also be concerned about integration execution, leverage and whether the expected strategic benefits justify the price. RTTNews report on Telix share decline

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. acquired a new position in Telix Pharmaceuticals in the second quarter valued at about $1,731,000. Private Advisor Group LLC increased its holdings in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock worth $1,669,000 after buying an additional 128,070 shares in the last quarter. XY Capital Ltd raised its stake in shares of Telix Pharmaceuticals by 468.0% in the second quarter. XY Capital Ltd now owns 71,291 shares of the company's stock valued at $822,000 after acquiring an additional 58,739 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock worth $2,775,000 after acquiring an additional 39,400 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock worth $96,000 after acquiring an additional 8,423 shares in the last quarter.

Telix Pharmaceuticals Stock Performance

The stock has a 50-day moving average of $11.30 and a 200 day moving average of $10.38. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company's commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.